ALCLS Cellectis SA

Cellectis to Report Third Quarter Financial Results on November 7, 2025

Cellectis to Report Third Quarter Financial Results on November 7, 2025

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market.

The press release will be available in the Investors section of Cellectis’ website:

Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit and follow Cellectis on LinkedIn and X.

For further information on Cellectis, please contact:

Media contacts:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer,

Attachment



EN
31/10/2025

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis to Present a Development Update for eti-cel at ASH 2025

Cellectis to Present a Development Update for eti-cel at ASH 2025 Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining eti-cel with low-dose IL-2 may deepen and extend anti-tumor activity in patients with r/r NHLEti-cel full Phase 1 dataset, including low-dose IL-2 combination cohorts, expected to be presented in 2026Correlation between alemtuzumab exposure and response with lasme-cel (UCART22) allows optimization of efficacy without an increase...

November 3, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis présentera de nouvelles avancées sur éti-cel lors du congrès...

Cellectis présentera de nouvelles avancées sur éti-cel lors du congrès annuel de l’ASH 2025 Les données préliminaires récemment présentées pour eti-cel (UCART20x22) montrent un taux de réponse global (ORR) de 86 % et un taux de réponse complète (CR) de 57 % (n=7), soulignant le potentiel de cette approche pour améliorer les résultats chez les patients atteints de lymphome non hodgkinien (LNH) en rechute ou réfractaireLes données précliniques sur le produit candidat éti-cel montrent que l’ajout d’une faible dose d’IL-2 pourrait renforcer et prolonger l’activité antitumorale chez les patients...

November 3, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis to Report Third Quarter Financial Results on November 7, 202...

Cellectis to Report Third Quarter Financial Results on November 7, 2025 NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: Cellectis will not host a c...

October 31, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis publiera ses résultats financiers du troisième trimestre le ...

Cellectis publiera ses résultats financiers du troisième trimestre le 7 novembre 2025 NEW YORK, 31 oct. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des thérapies cellulaires et géniques, publiera ses résultats financiers pour le troisième trimestre clos au 30 septembre 2025, le vendredi 7 novembre 2025 après la clôture du marché aux États-Unis. Le communiqué de presse sera disponible dans la section “Investisseurs” du site internet de Cellect...

October 31, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Signifi...

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL  ○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability: in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months ○ In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status ○ In the target Phase 2 population, 100% p...

October 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch